You are here

HIV DIPSTICK FOR RESORUCE-LIMITED BLOOD BANKS

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43HL071494-01
Agency Tracking Number: HL071494
Amount: $127,155.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2002
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
DIAGNOSTICS FOR THE REAL WORLD 50 MOUNDS RD
SAN MATEO, CA 94402
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 HELEN LEE
 (408) 687-2315
 HH1207@AOL.COM
Business Contact
 VIVIAN LAITILA
Phone: (408) 996-7479
Email: VIVFL@MINDSPRING.COM
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): According to WHO statistics on blood safety, 80 percent of the world's population has access to 20 percent of the world's safe blood supply. However, more than 20 percent (13,000,000 units) of the world blood supply is not tested for the three major transfusion-transmissible infections: HIV, HBV and HCV. Transfusion of unsafe blood accounts for 80,000-160,000 HIV infections each year. The problem is especially severe in resource-poor countries where the availability of safe blood clearly needs to be increased, If inexpensive, rapid, improved dipsticks with sensitivity comparable to EIA were developed for blood screening, it would greatly improve the safety of the blood supply in developing countries.The overall aim of the project is to develop an HIV dipstick assay with high sensitivity, designated as the reflex diagnostic. The test can be used in developed countries under circumstances where an immediate result is required. For the developing countries, we propose that this test be integrated into a triplex test (HBV, HIV & HCV) and used as the initial step of pre-donation screening in high prevalence countries. The associated second step is to use the HIV reflex diagnostic test in order to identify the agent responsible for the positive Triplex test result.The specific aims of Phase I are to clone and express the HIV-1 trans- membrane glycoprotein (gp4l), HIV-1 integrase (p-32) and HIV-2 trans-membrane glycoprotein (gp36). We intend to screen and select immuno-reactive clones and produce the reagents in milligram quantities for test development.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government